BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 996 filers reported holding BAXTER INTL INC in Q2 2015. The put-call ratio across all filers is 0.74 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $1,612,000 | +3.7% | 25,686 | +0.1% | 0.03% | 0.0% |
| Q2 2017 | $1,554,000 | +12.9% | 25,665 | -3.3% | 0.03% | +11.1% |
| Q1 2017 | $1,376,000 | -9.3% | 26,531 | -22.4% | 0.03% | -10.0% |
| Q4 2016 | $1,517,000 | -10.3% | 34,204 | -3.8% | 0.03% | -21.1% |
| Q3 2016 | $1,692,000 | -1.9% | 35,548 | -6.8% | 0.04% | -11.6% |
| Q2 2016 | $1,724,000 | +6.6% | 38,122 | -3.2% | 0.04% | +7.5% |
| Q1 2016 | $1,618,000 | -4.1% | 39,378 | -11.0% | 0.04% | -7.0% |
| Q4 2015 | $1,688,000 | +14.3% | 44,250 | -1.6% | 0.04% | +10.3% |
| Q3 2015 | $1,477,000 | -34.1% | 44,958 | +40.3% | 0.04% | -27.8% |
| Q2 2015 | $2,241,000 | -4.0% | 32,040 | -6.0% | 0.05% | -6.9% |
| Q1 2015 | $2,335,000 | -5.7% | 34,086 | +0.9% | 0.06% | -4.9% |
| Q4 2014 | $2,476,000 | +0.0% | 33,784 | -2.1% | 0.06% | -3.2% |
| Q3 2014 | $2,475,000 | +0.4% | 34,492 | +1.1% | 0.06% | -1.6% |
| Q2 2014 | $2,466,000 | +6.6% | 34,101 | +8.5% | 0.06% | -1.5% |
| Q1 2014 | $2,313,000 | -4.1% | 31,431 | -9.3% | 0.06% | -4.4% |
| Q4 2013 | $2,411,000 | +3.3% | 34,666 | -2.4% | 0.07% | -5.6% |
| Q3 2013 | $2,333,000 | -14.0% | 35,509 | -9.4% | 0.07% | -18.2% |
| Q2 2013 | $2,714,000 | – | 39,181 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |